C4 Therapeutics Inc
NASDAQ:CCCC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.18
11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
C4 Therapeutics Inc
Operating Margin
C4 Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | US |
| Market Cap | 302m USD |
| Operating Margin |
-347%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 320.1B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 147.4B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 119.4B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 113.8B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 82.6B USD |
| Operating Margin |
30%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Operating Margin |
-22%
|
C4 Therapeutics Inc
Glance View
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on C4 Therapeutics Inc's most recent financial statements, the company has Operating Margin of -347.2%.
You don't have any saved screeners yet
